References Copeptin

Ref-1: Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem. 1972; 28: 334-339.

Ref-2: Land H, Schutz G, Schmale H and Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature. 1982; 295: 299-303.

Ref-3: Struck J, Morgenthaler NG and Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005; 26: 2500-2504.

Ref-4: Morgenthaler NG, Struck J, Alonso C and Bergmann A. Assay for the measurement of copeptin, a stable Peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52: 112-119.

Ref-5: Morgenthaler NG, Struck J, Jochberger S and Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008; 19: 43-49.

Ref-6: Acher R, Chauvet J and Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci. 2002; 18: 223-228.

Ref-7: Repaske DR, Medlej R, Gultekin EK, Krishnamani MR, Halaby G, Findling JW and Phillips JA, 3rd. Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab. 1997; 82: 51-56.

Ref-8: Gillies GE, Linton EA and Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982; 299: 355-357.

Ref-9: Rivier C and Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983; 305: 325-327.

Ref-10: Rivier C and Vale W. Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology. 1983; 113: 939-942.

Ref-11: Milsom SR, Conaglen JV, Donald RA, Espiner EA, Nicholls MG and Livesey JH. Augmentation of the response to CRF in man: relative contributions of endogenous angiotensin and vasopressin. Clin Endocrinol (Oxf). 1985; 22: 623-629.

Ref-12: Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000; 11: 406-410.

Ref-13: Holmes CL, Landry DW and Granton JT. Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Crit Care. 2003; 7: 427-434.

Ref-14: Holmes CL, Landry DW and Granton JT. Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology. Crit Care. 2004; 8: 15-23.

Ref-15: Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN and Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997; 138: 4109-4122.

Ref-16: Peter J, Burbach H, Adan RA, Lolait SJ, van Leeuwen FW, Mezey E, Palkovits M and Barberis C. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol. 1995; 15: 573-595.

Ref-17: Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA and Erzurum SC. Human vascular endothelial cells express oxytocin receptors. Endocrinology. 1999; 140: 1301-1309.

Ref-18: Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH and McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A. 1997; 94: 11704-11709.

Ref-19: Zenteno-Savin T, Sada-Ovalle I, Ceballos G and Rubio R. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol. 2000; 410: 15-23.

Ref-20: Bhandari SS, Loke I, Davies JE, Squire IB, Struck J and Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009; 116: 257-263.

Ref-21: Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U and Christ-Crain M. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007.

Ref-22: Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Muller B and Christ-Crain M. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab. 2007; 92: 2640-2643.

Ref-23: Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG and Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009; 94: 123-129.

Ref-24: Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW and Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology. 1992; 77: 662-668.

Ref-25: Krismer AC, Wenzel V, Stadlbauer KH, Mayr VD, Lienhart HG, Arntz HR and Lindner KH. Vasopressin during cardiopulmonary resuscitation: a progress report. Crit Care Med. 2004; 32: S432-435.

Ref-26: Mutlu GM and Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004; 30: 1276-1291.

Ref-27: Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH and Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med. 2004; 350: 105-113.

Ref-28: Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B and Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003; 107: 2313-2319.

Ref-29: Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H and Christ-Crain M. Copeptin, a Stable Peptide of the Arginine Vasopressin Precursor, Is Elevated in Hemorrhagic and Septic Shock. Shock. 2007.

Ref-30: Arnauld E, Czernichow P, Fumoux F and Vincent JD. The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta). Pflugers Arch. 1977; 371: 193-200.

Ref-31: Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A and Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007; 115: 2103-2110.

Ref-32: Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M and Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 60-68.

Ref-33: Keller T and Blankenberg S. Copeptin Improves Early Diagnosis of Acute Myocardial Infarction. Circulation. 2009; 120: S1035.

Ref-34: Jaffe AS and Apple FS. High-sensitivity cardiac troponin: hype, help, and reality. Clin Chem. 56: 342-344.

Ref-35: CHOPIN. Copeptin Helps in the early detection Of Patients with acute myocardial INfarction. 2010.

Ref-36: Schaller MD, Nicod P, Nussberger J, Feihl F, Waeber B, Brunner HR and Perret C. [Vasopressin in acute myocardial infarct: clinical implications]. Schweiz Med Wochenschr. 1986; 116: 1727-1729.

Ref-37: McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G and Dargie HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988; 60: 117-124.

Ref-38: Donald RA, Crozier IG, Foy SG, Richards AM, Livesey JH, Ellis MJ, Mattioli L and Ikram H. Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction. Clin Endocrinol (Oxf). 1994; 40: 499-504.

Ref-39: Charles CJ, Rogers SJ, Donald RA, Ikram H, Prickett T and Richards AM. Hypothalamo-pituitary-adrenal axis response to coronary artery embolization: an ovine model of acute myocardial infarction. J Endocrinol. 1997; 152: 489-493.

Ref-40: Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B and Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008; 29: 341-346.

Ref-41: Griebel G, Stemmelin J, Gal CS and Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des. 2005; 11: 1549-1559.

Ref-42: Henriksen JH and Moller S. Haemodynamics and fluid retention in liver disease. Ital J Gastroenterol Hepatol. 1998; 30: 320-332.

Ref-43: Griebel G, Simiand J, Stemmelin J, Gal CS and Steinberg R. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord. 2003; 2: 191-200.

Ref-44: Goldsmith SR. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail. 2002; 8: 251-256.

Ref-45: Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP and Le Fur G. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002; 139: 197-210.

Ref-46: Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F and et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993; 22: 390-398.

Ref-47: Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F and et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994; 24: 583-591.

Ref-48: Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A and Pacher R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006; 36: 771-778.

Ref-49: Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M and Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007; 13: 42-49.

Ref-50: Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, Davies JE and Ng LL. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail. 2008; 14: 739-745.

Ref-51: Fukuzawa J, Haneda T and Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999; 195: 93-98.

Ref-52: Goldsmith SR. Vasopressin as vasopressor. Am J Med. 1987; 82: 1213-1219.

Ref-53: Fan YH, Zhao LY, Zheng QS, Dong H, Wang HC and Yang XD. Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. Life Sci. 2007; 81: 327-335.

Ref-54: Konstam MA, Gheorghiade M, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C and Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. Jama. 2007; 297: 1319-1331.

Ref-55: Gheorghiade M, Konstam MA, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C and Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. Jama. 2007; 297: 1332-1343.

Ref-56: Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, Sasamata M and Miyata K. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005; 507: 145-151.

Ref-57: Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R and Pacher R. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52: 266-272.

Ref-58: Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ and Dickstein K. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009; 30: 1187-1194.

Ref-59: Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B and Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009; 66: 799-808.

Ref-60: Vachharajani TJ, Zaman F and Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. 2003; 18: 3-8.

Ref-61: Hoorn EJ, Halperin ML and Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. Qjm. 2005; 98: 529-540.

Ref-62: Hoorn EJ, Geary D, Robb M, Halperin ML and Bohn D. Acute hyponatremia related to intravenous fluid administration in hospitalized children: an observational study. Pediatrics. 2004; 113: 1279-1284.

Ref-63: Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N and Bankir L. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant. 2003; 18: 497-506.

Ref-64: Fernandes S, Bruneval P, Hagege A, Heudes D, Ghostine S and Bouby N. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology. 2002; 143: 2759-2766.

Ref-65: Bouby N, Bachmann S, Bichet D and Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol. 1990; 258: F973-979.

Ref-66: Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E and Hori M. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int. 1999; 55: 1800-1810.

Ref-67: Bardoux P, Bruneval P, Heudes D, Bouby N and Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant. 2003; 18: 1755-1763.

Ref-68: Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J and Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 77: 29-36.

Ref-69: Cirillo M. Determinants of kidney dysfunction: is vasopressin a new player in the arena? Kidney Int. 77: 5-6.

Ref-70: Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP and Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009; 88: 561-567.

Ref-71: Dunser MW, Schmittinger CA and Torgersen C. Copeptin and the transplanted kidney: friends or foes? Transplantation. 2009; 88: 455-456.

Ref-72: Golestaneh L, Talreja A and Le Jemtel TH. Vasopressin antagonists in heart failure. Curr Heart Fail Rep. 2004; 1: 190-196.

Ref-73: Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS and Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-2112.

Ref-74: Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H and Djian J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003; 124: 933-939.

thermo scientific applied biosystems invitrogen fisher scientific unity lab service